Novartis’ new MS drug (FTY 720) looking good in Phase III trials. New results just released.
Vertex – takeover target? For a company looking to expand into Hepatitis C, Vertex is a prime candidate.
Boston Scientific and J&J making peace with the lawyer-enriching stent suits.
Call center/phone rep training. The Impactiviti Partner Network has great providers to help you with this need. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Connect with Steve Woodruff